Limits...
Validation of anti-aging drugs by treating age-related diseases.

Blagosklonny MV - Aging (Albany NY) (2009)

Bottom Line: All together age-related diseases are the best biomarker of aging.If the group is large, then the anti-aging effect could be validated in a couple of years.Startlingly, retrospective analysis of clinical and preclinical data reveals four potential anti-aging modalities.

View Article: PubMed Central - PubMed

Affiliation: Cancer Center, Ordway Research Institute, Albany, NY 12208, USA.

ABSTRACT
Humans die from age-related diseases, which are deadly manifestations of the aging process. In order to extend life span, an anti-aging drug must delay age-related diseases. All together age-related diseases are the best biomarker of aging. Once a drug is used for treatment of any one chronic disease, its effect against other diseases (atherosclerosis, cancer, prostate enlargement, osteoporosis, insulin resistance, Alzheimer's and Parkinson's diseases, age-related macular degeneration) may be evaluated in the same group of patients. If the group is large, then the anti-aging effect could be validated in a couple of years. Startlingly, retrospective analysis of clinical and preclinical data reveals four potential anti-aging modalities.

Show MeSH

Related in: MedlinePlus

The TOR intracellular signaling pathway. Nutrients, GF (growth factors)                                            and insulin activate the TOR pathway, which is involved in aging and                                            age-related diseases. Other genetic factors and environmental factors                                            (e.g., smoking) contribute to specific age-related diseases. Three                                            potential anti-aging modalities (metformin, calorie restriction and                                            rapamycin) all inhibit the TOR pathway.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2806014&req=5

Figure 1: The TOR intracellular signaling pathway. Nutrients, GF (growth factors) and insulin activate the TOR pathway, which is involved in aging and age-related diseases. Other genetic factors and environmental factors (e.g., smoking) contribute to specific age-related diseases. Three potential anti-aging modalities (metformin, calorie restriction and rapamycin) all inhibit the TOR pathway.

Mentions: Numerous factors including insulin, glucose and amino acids activate the nutrient-sensing TOR (target of rapamycin) pathway. When the TOR pathway is activated, it acts via S6K to deplete the insulin-receptor-substrate (IRS1/2), causing insulin resistance (Figure 1). As shown in Figure 1, metformin indirectly (by activating AMPK) inhibits TOR and thereby restores insulin sensitivity [26].


Validation of anti-aging drugs by treating age-related diseases.

Blagosklonny MV - Aging (Albany NY) (2009)

The TOR intracellular signaling pathway. Nutrients, GF (growth factors)                                            and insulin activate the TOR pathway, which is involved in aging and                                            age-related diseases. Other genetic factors and environmental factors                                            (e.g., smoking) contribute to specific age-related diseases. Three                                            potential anti-aging modalities (metformin, calorie restriction and                                            rapamycin) all inhibit the TOR pathway.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2806014&req=5

Figure 1: The TOR intracellular signaling pathway. Nutrients, GF (growth factors) and insulin activate the TOR pathway, which is involved in aging and age-related diseases. Other genetic factors and environmental factors (e.g., smoking) contribute to specific age-related diseases. Three potential anti-aging modalities (metformin, calorie restriction and rapamycin) all inhibit the TOR pathway.
Mentions: Numerous factors including insulin, glucose and amino acids activate the nutrient-sensing TOR (target of rapamycin) pathway. When the TOR pathway is activated, it acts via S6K to deplete the insulin-receptor-substrate (IRS1/2), causing insulin resistance (Figure 1). As shown in Figure 1, metformin indirectly (by activating AMPK) inhibits TOR and thereby restores insulin sensitivity [26].

Bottom Line: All together age-related diseases are the best biomarker of aging.If the group is large, then the anti-aging effect could be validated in a couple of years.Startlingly, retrospective analysis of clinical and preclinical data reveals four potential anti-aging modalities.

View Article: PubMed Central - PubMed

Affiliation: Cancer Center, Ordway Research Institute, Albany, NY 12208, USA.

ABSTRACT
Humans die from age-related diseases, which are deadly manifestations of the aging process. In order to extend life span, an anti-aging drug must delay age-related diseases. All together age-related diseases are the best biomarker of aging. Once a drug is used for treatment of any one chronic disease, its effect against other diseases (atherosclerosis, cancer, prostate enlargement, osteoporosis, insulin resistance, Alzheimer's and Parkinson's diseases, age-related macular degeneration) may be evaluated in the same group of patients. If the group is large, then the anti-aging effect could be validated in a couple of years. Startlingly, retrospective analysis of clinical and preclinical data reveals four potential anti-aging modalities.

Show MeSH
Related in: MedlinePlus